Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
3.
Neurology ; 99(13): 559-566, 2022 09 27.
Article in English | MEDLINE | ID: mdl-35918173

ABSTRACT

OBJECTIVES: To describe long-term follow-up brain MRI findings in patients with cerebrotendinous xanthomatosis (CTX) treated with chenodeoxycholic acid (CDCA). METHODS: Of a cohort of 79 Dutch patients with CTX, we retrospectively reviewed brain MRI findings of patients at diagnosis (before the start of treatment) and after long-term follow-up (7-27 years) in 12 patients. In addition, we report on 2 families with remarkable brain MRI findings. RESULTS: MRI abnormalities showed progression in all 7 patients diagnosed at 24 years or older and only in 1 of 5 patients diagnosed younger than 24 years. MRI findings in the other patients diagnosed younger than 24 years were normal at baseline and remained normal even after follow-up of more than 25 years. The total MRI scores at baseline were 2 and 19 and at follow-up 4 and 37, respectively, for patients diagnosed before or after the age of 24 years, despite a comparable number of treatment years. DISCUSSION: MRI findings are fully in line with our long-term treatment effect article, emphasizing the importance of early diagnosis and treatment in CTX. Expanding the spectrum of brain MRI findings (including the finding of a posterior leukoencephalopathy) leads to a better understanding of the heterogeneity of this treatable disease.


Subject(s)
Xanthomatosis, Cerebrotendinous , Adult , Chenodeoxycholic Acid/therapeutic use , Cohort Studies , Humans , Magnetic Resonance Imaging , Retrospective Studies , Xanthomatosis, Cerebrotendinous/diagnostic imaging , Xanthomatosis, Cerebrotendinous/drug therapy , Young Adult
6.
BMJ Case Rep ; 14(9)2021 Sep 03.
Article in English | MEDLINE | ID: mdl-34479889

ABSTRACT

A 55-year-old man with mental retardation and calcaneal tendon thickening was referred for a suspected genetic disease. His serum cholestanol was elevated and genetic analysis of his blood cells for CYP27A1 revealed a homozygous missense mutation. We diagnosed him with cerebrotendinous xanthomatosis (CTX). Chest radiography revealed diffuse micronodular and reticular opacities. Histological findings obtained from the transbronchial lung biopsy revealed foamy macrophages and multinucleate giant cells with marked lipid crystal clefts. Although there are few reports of pulmonary lesions in CTX, we concluded from the radiological and histopathological findings that the pulmonary lesions were indeed caused by the CTX. The patient was treated with chenodeoxycholic acid. His neurological findings and calcaneal tendon thickening were unchanged; however, his serum cholestanol and radiological abnormalities of the chest decreased.


Subject(s)
Xanthomatosis, Cerebrotendinous , Chenodeoxycholic Acid/therapeutic use , Cholestanetriol 26-Monooxygenase , Cholestanol , Humans , Male , Middle Aged , Radiography , Xanthomatosis, Cerebrotendinous/diagnostic imaging , Xanthomatosis, Cerebrotendinous/drug therapy
8.
Medicine (Baltimore) ; 100(9): e24687, 2021 Mar 05.
Article in English | MEDLINE | ID: mdl-33655933

ABSTRACT

RATIONALE: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid deposition disorder characterized by systemic signs and neurological dysfunction. The radiological features of CTX are infrequently summarized in the literature. PATIENT CONCERNS: We described a 40-year-old male patient who repeatedly engaged in wrestling matches and presented with progressive difficulty in walking and reduced balance with egg-sized, hard, smooth, and painless masses in both ankles. DIAGNOSIS: Neuroimaging examination showed abnormalities both supra- and infratentorially. Bilateral ankle joint magnetic resonance imaging showed bilateral xanthomata of the Achilles tendon. The diagnosis was confirmed by the detection of a sterol 27-hydroxylase gene mutation. INTERVENTIONS: The patient was treated with chenodeoxycholic acid (250 mg 3 times per day). OUTCOMES: To date, the patient's bilateral xanthomas of the Achilles tendon have begun to diminish, and his neurological impairment has not deteriorated further but has not yet improved. LESSONS: We report a rare case of CTX and summarize the clinical and imaging features of this disease. Our findings suggest that the abnormal signals in the dentate nucleus or a long spinal cord lesion involving the central and posterior cord, combined with tendon xanthoma, are important clues for the diagnosis of CTX.


Subject(s)
Magnetic Resonance Imaging/methods , Nervous System Diseases/congenital , Xanthomatosis, Cerebrotendinous/complications , Achilles Tendon/diagnostic imaging , Achilles Tendon/pathology , Adult , Ankle Joint/diagnostic imaging , Ankle Joint/pathology , Chenodeoxycholic Acid/therapeutic use , Humans , Male , Nervous System Diseases/diagnostic imaging , Nervous System Diseases/pathology , Xanthomatosis, Cerebrotendinous/diagnostic imaging , Xanthomatosis, Cerebrotendinous/pathology
9.
Acta Neurol Belg ; 121(2): 561-566, 2021 Apr.
Article in English | MEDLINE | ID: mdl-31875301

ABSTRACT

Cerebrotendinous Xanthomatosis (CTX) is an autosomal recessive defect of the alternative pathway of bile acid biosynthesis, due to the deficiency of mitochondrial cytochrome P450 sterol 27-hydroxylase enzyme encoded by CYP27A1. The deficit of sterol 27-hydroxylase raises cholestanol in plasma and tissues of affected patients. Although there is a marked variability of signs, symptoms, severity and age of onset, the main clinical manifestations of CTX include chronic diarrhea, bilateral cataract, tendon xanthomas and neurological dysfunction. Herein, we report the clinical, biochemical and molecular characterization of a Caucasian female affected by CTX diagnosed at 28 years. The patient's clinical history revealed neurological and behavioral manifestations already at fifth year of life, following by bilateral cataract and chronic diarrhea without xanthomas. At diagnosis, an involvement of the cervical spinal cord was also observed on MRI. Sterols profile analysis in plasma and red blood cell membranes showed very high cholestanol levels. CYP27A1 sequencing revealed a new variant (e.g., c.850_854delinsCTC) at homozygous status. The follow-up after 5 months of chenodeoxycholic acid treatment showed a decrease of plasma cholestanol of 64%. After 1 year, the patient showed normalization of bowel function, reduction of risk of falls, improvement of cognitive function although brain and spine MRI and other instrumental examinations remained unchanged. This case highlights the variability of the CTX phenotype that makes it difficult to reach an early diagnosis. Biochemical and/or molecular screening of CTX should be taken into account to early start the pharmacological treatment limiting neurological damages.


Subject(s)
Cholestanetriol 26-Monooxygenase/genetics , Spinal Cord Diseases/genetics , Tendons , Xanthomatosis, Cerebrotendinous/genetics , Xanthomatosis , Chenodeoxycholic Acid/therapeutic use , Female , Humans , Spinal Cord Diseases/diagnostic imaging , Spinal Cord Diseases/etiology , Xanthomatosis, Cerebrotendinous/complications , Xanthomatosis, Cerebrotendinous/diagnostic imaging , Young Adult
11.
Clin Neurophysiol ; 131(8): 1798-1803, 2020 08.
Article in English | MEDLINE | ID: mdl-32531740

ABSTRACT

OBJECTIVE: To characterize peripheral nerve morphology in cerebrotendinous xanthomatosis (CTX) patients using high-resolution ultrasound (HRUS) in vivo. We hypothesized that nerve enlargements might be present in CTX as a result of accumulation of abnormal lipids with deposition also in peripheral nerves. METHODS: Four CTX patients were examined using HRUS to assess morphological abnormalities of peripheral nerves as well as cervical nerve roots 5 and 6. RESULTS: HRUS revealed mild to moderate, hypoechogenic thickening of sensorimotor nerves (ulnar nerve in 1/4, tibial nerve in 3/4, median nerve 4/4 patients) as well as mild enlargement of pure sensory nerves (sural nerve in 2/3, superficial FN in 2/4 patients). The vagal nerve was moderately enlarged in one patient, cervical roots showed moderate enlargements of C5 in two patients, one of which also showing thickening of C6 as well as in another patient. UPSS score was slightly to moderately abnormal in all patients. The Homogeneity score was not increased suggesting regional to inhomogeneous nerve enlargement. CONCLUSIONS: HRUS shows multifocal, hypoechogenic nerve thickening of peripheral nerves and nerve roots in CTX. SIGNIFICANCE: HRUS might serve as a valuable, additive and non-invasive bedside tool to assess peripheral nerve morphology in future clinical studies on CTX patients.


Subject(s)
Neural Conduction/physiology , Peripheral Nerves/diagnostic imaging , Ultrasonography/methods , Xanthomatosis, Cerebrotendinous/diagnostic imaging , Adult , Female , Humans , Male , Median Nerve/diagnostic imaging , Median Nerve/physiopathology , Middle Aged , Peripheral Nerves/physiopathology , Sural Nerve/diagnostic imaging , Sural Nerve/physiopathology , Tibial Nerve/diagnostic imaging , Tibial Nerve/physiopathology , Ulnar Nerve/diagnostic imaging , Ulnar Nerve/physiopathology , Vagus Nerve/diagnostic imaging , Vagus Nerve/physiopathology , Xanthomatosis, Cerebrotendinous/physiopathology
13.
Rev Med Chil ; 147(5): 658-662, 2019 May.
Article in Spanish | MEDLINE | ID: mdl-31859899

ABSTRACT

Cerebrotendinous xanthomatosis (CTX) is an uncommon autosomal recessive disease caused by deficiency of 27-sterol-hydroxylase that results in an accumulation of cholestanol in the central nervous system, eyes, tendons, and blood vessels. We report a 22-year-old woman with a history of cataract surgery at the age of 14, cholecystectomy due to cholelithiasis at the age of 17 and chronic diarrhea, who presented with a six months period of gait instability and frequent falls. Physical examination revealed a bilateral pyramidal and cerebellar syndrome, with no visible tendon xanthomas. Cerebral magnetic resonance imaging showed an increase of the signal intensity on the T2-weighted images in periventricular cerebral white matter, dentate nuclei and spinal cord. With a high suspicion of CXT, a genetic study was conducted identifying a pathogenic variant in the CYP27A1 gene. There is considerable variation in clinical characteristics and age of onset of this disease, including absence of tendon xanthomas, delaying the diagnosis. Early recognition and chronic chenodeoxycholic acid therapy can improve outcome and quality of life.


Subject(s)
Chenodeoxycholic Acid/therapeutic use , Xanthomatosis, Cerebrotendinous/diagnostic imaging , Xanthomatosis, Cerebrotendinous/drug therapy , Cholestanetriol 26-Monooxygenase/genetics , Cholestanol/blood , Early Diagnosis , Female , Humans , Magnetic Resonance Imaging , Vitamin D/therapeutic use , Xanthomatosis, Cerebrotendinous/genetics , Young Adult
16.
Rev. méd. Chile ; 147(5): 658-662, mayo 2019. graf
Article in Spanish | LILACS | ID: biblio-1014275

ABSTRACT

Cerebrotendinous xanthomatosis (CTX) is an uncommon autosomal recessive disease caused by deficiency of 27-sterol-hydroxylase that results in an accumulation of cholestanol in the central nervous system, eyes, tendons, and blood vessels. We report a 22-year-old woman with a history of cataract surgery at the age of 14, cholecystectomy due to cholelithiasis at the age of 17 and chronic diarrhea, who presented with a six months period of gait instability and frequent falls. Physical examination revealed a bilateral pyramidal and cerebellar syndrome, with no visible tendon xanthomas. Cerebral magnetic resonance imaging showed an increase of the signal intensity on the T2-weighted images in periventricular cerebral white matter, dentate nuclei and spinal cord. With a high suspicion of CXT, a genetic study was conducted identifying a pathogenic variant in the CYP27A1 gene. There is considerable variation in clinical characteristics and age of onset of this disease, including absence of tendon xanthomas, delaying the diagnosis. Early recognition and chronic chenodeoxycholic acid therapy can improve outcome and quality of life.


Subject(s)
Humans , Female , Young Adult , Chenodeoxycholic Acid/therapeutic use , Xanthomatosis, Cerebrotendinous/drug therapy , Xanthomatosis, Cerebrotendinous/diagnostic imaging , Vitamin D/therapeutic use , Magnetic Resonance Imaging , Cholestanol/blood , Xanthomatosis, Cerebrotendinous/genetics , Early Diagnosis , Cholestanetriol 26-Monooxygenase/genetics
SELECTION OF CITATIONS
SEARCH DETAIL